Besides regulating lipid metabolism, statins have garnered considerable interest because of their antiviral and antineoplastic properties.
The potential benefit of statins using in chronic hepatitis C patients is not well described.
Dr Yi-Xiang Zheng and colleagues quantitatively assessed the efficacy of statins in improving the therapeutic effect and prognosis of patients with chronic hepatitis C.
The team searched electronic databases for relevant studies comparing the course of benefit in chronic hepatitis C patients with statins versus without statins.
|The sustained virological response rate increased by 31% in 12, 791 chronic hepatitis C patients with statins |
|European Journal of Gastroenterology & Hepatology|
Risk estimates were pooled to assess the association of statins use with sustained virological response and the prognosis of chronic hepatitis C patients.
The research team identified 23 studies that fulfilled the inclusion criteria.
Meta-analysis of 16 homogeneous studies showed that the sustained virological response rate increased by 31% in 12, 791 chronic hepatitis C patients with statins as an adjuvant under the general antiviral therapy compared with those without this adjuvant therapy.
The team showed that 7 studies suggested that statins was beneficial on several specific poor outcomes of chronic hepatitis C patients.
The research team found that chronic hepatitis C patients with statin use were inversely associated with a 55% reduced risk of hepatocellular carcinoma, and 53% reduced risk of cirrhosis as well as 44% reduced risk of mortality.
Dr Zheng's team comments, "Beneficial effects of statins use were found in the therapy and the prognosis of chronic hepatitis C patients."
"Further prospective studies are still needed to confirm these benefits."